IN THE NEWS
January 31, 2023
eQcell Inc. listed for the Innovation Showcase of "Twenty game-changing start-ups" at the International Animal Health, Nutrition & Technology Innovation Forum, Europe (London, March 6-8, 2023) read more...
David Allan, Managing Director of eQcell Inc. selected among the Top 25 Healthcare Technology Leaders of Toronto for 2022
Science reshapes the future
A Canadian Regenerative Medicine Company
"In my opinion, Dr. Koch and his team have a novel plan based on good science to develop a licensable and commercially-available allogeneic MSC product for veterinary use.” “I was also compelled by eQcell’s translational approach using animal data to inform similar human cell therapies which I believe hold tremendous promise to improve human health in addition to equine welfare... I have favored the One Health concept for years, so it is very exciting to be part of a company pursuing this strategy.”
Dr. C. Wayne McIlwraith
Distinguished Professor and Founding Director, Colorado State University's Orthopedic Research Center
eQcell Inc. is Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells as well as canine adipose-derived mesenchymal stromal cells designed to provide veterinarians around the world with off-the-shelf therapeutics with increased efficacy and predictability over the current, laborious and expensive autologous stem cell treatments that extract, expand and re-inject a horse's own cells.